ArticleJournal of family medicine and primary care2025
Persistent miller fisher syndrome following COVID-19 infection: A case report.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Guillain-Barré syndrome (GBS) is an inflammatory disease of the peripheral nervous system, with Miller-Fisher syndrome (MFS) being a rare variant. Recent studies have shown GBS and MFS to be a common side effect of COVID-19. This case report highlights the clinical presentation of a patient diagnosed with post-COVID-19 MFS, their subsequent treatment challenges, and the prognostic outcomes, contributing to the limited scientific literature of this uncommon affliction. A comprehensive case report of a 57-year-old man with significant medical history was conducted to determine the appropriate diagnosis based on the perceived symptoms following COVID-19. Per the Northwell health human research protection program, the publication of case reports involving up to three patients is not considered human-subject research and does not require IRB review and approval. Our patient was diagnosed with MFS, making him the longest-known adult with COVID-19-associated MFS without resolution of neurologic symptoms after intravenous immunoglobulin (IVIG) dose administration. Our case report posits the first-known patient to have a more severe form of MFS or resistance to IVIG dose. The current study also highlights the association between COVID-19 and MFS, warranting the need for more studies to understand the disease pathophysiology and new biomarkers for targeted treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.